Uncategorized – Page 8

Women With Early Cervical Cancer Who Conceived At Least Three Months After Fertility-Sparing Surgery Had High Live Birth Rate

Posted on March 25, 2021 by Womens Cancer Care

Healio (3/24, Leiser) reports, “Women with early cervical cancer who conceived at least 3 months after fertility-sparing surgery had a high live birth rate, according to results presented at” the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer. However, Healio says, “these women had elevated risks for preterm delivery and neonatal morbidity compared with […]

Rucaparib Significantly Improved PFS Compared With Chemo In Patients With BRCA-Mutated, Advanced, Relapsed Ovarian Cancer

Posted on March 22, 2021 by Womens Cancer Care

MD Edge ObGyn (3/21, Osterweil) reports, “The PARP inhibitor rucaparib significantly improved progression-free survival (PFS) compared with standard-of-care chemotherapy in women with BRCA-mutated, advanced, relapsed ovarian cancer in the phase 3 ARIEL4 study.” The findings from ARIEL4 were presented at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer. MedPage Today (3/20, Bankhead) reported, “Treatment with […]

Researchers Study Impact Of Delayed Or Cancelled Cancer Screenings Due To COVID-19 Pandemic

Posted on March 20, 2021 by Womens Cancer Care

The AP (3/16, Marchione) reports, “Millions of colonoscopies, mammograms, lung scans, Pap tests and other cancer screenings were suspended for several months last spring in the United States and elsewhere as COVID-19 swamped medical care.” The AP adds, “Now researchers are studying the impact, looking to see how many cancers were missed and whether tumors found since then […]

Patients Consider Risk Of Menopause, Cancer When Making Ovarian Cancer Prevention Surgery Decisions

Posted on March 15, 2021 by Womens Cancer Care

Medscape (3/5, Otto, Subscription Publication) reported, “Patients consider the risk of cancer and menopause, as well as other factors, when making decisions about ovarian cancer prevention surgery, according to a small study.” Researchers “interviewed 24 premenopausal women with BRCA mutations who were considering prophylactic surgery,” and “responses showed that women who prioritized cancer risk reduction opted for […]

Continuing Treatment With Bevacizumab Beyond Progression Improved PFS Compared With Chemo Alone For Patients With Recurrent Ovarian Cancer, Study Shows

Posted on March 15, 2021 by Womens Cancer Care

Cancer Network (3/13, Fowler) reported, “Continuing treatment with bevacizumab (Avastin) beyond progression improved progression-free survival for patients with platinum-sensitive recurrent ovarian cancer compared with chemotherapy alone, according to data published in The Lancet Oncology.” The study results “sought to determine the value of continued bevacizumab treatment after progression following first-line treatment, suggesting this therapeutic path could be considered […]

Researchers Outline How Germline Genetic Testing Has Evolved Over Time In Women With Breast Or Ovarian Cancer

Posted on March 9, 2021 by Womens Cancer Care

Medscape (3/8, Lyss, Subscription Publication) reports, “A large, retrospective study shows how germline genetic testing has evolved over time in women with breast or ovarian cancer and reveals a path forward for testing these patients.” The study’s authors “found racial and ethnic disparities in genetic testing as well as ‘persistent underuse’ of testing in patients with […]

FDA Authorizes Surgical Robot Designed For Transvaginal Hysterectomies

Posted on March 3, 2021 by Womens Cancer Care

FierceBiotech (3/2, Hale) reports the FDA has “cleared its first surgical robot designed for transvaginal hysterectomies, a minimally invasive option that aims for a faster recovery time compared to procedures that require a larger abdominal incision.” FierceBiotech adds, “Memic Innovative Surgery’s Hominis system is intended to assist with the removal of the uterus, along with one or […]

Number Of Genes Tested For Ovarian, Breast Cancer Has Grown, But Most Patients Don’t Undergo Testing

Posted on March 3, 2021 by Womens Cancer Care

Cancer Therapy Advisor (3/1, Bennett) reports, “The number of genes tested for ovarian and breast cancer has grown in recent years, but most patients do not undergo testing. Thus, variant-of-unknown-significance (VUS) results are common, especially among minority populations, according to the results of a study published in the Journal of Clinical Oncology.” The study “results revealed that testing was […]

Treatment With A Carboplatin-Based Doublet Plus Bevacizumab Beyond Disease Progression Significantly Improved Progression-Free Survival Vs A Carboplatin-Based Doublet Alone In Women With Platinum-Sensitive Ovarian Cancer In Phase 3 Trial

Posted on February 24, 2021 by Womens Cancer Care

The ASCO Post (2/23, Stenger) reports researchers found in the phase 3 MITO16b/MANGO-OV2/ENGOT-ov17 trial “found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer who experienced disease recurrence after first-line treatment with a platinum-based therapy plus bevacizumab.” The trial’s results were published in […]

Researchers Identify Genetic Changes In Tumors That May Predict Efficacy Of Immunotherapy Drugs

Posted on February 15, 2021 by Womens Cancer Care

Medscape (2/10, Nelson, Subscription Publication) reports researchers in the UK “have identified genetic changes in tumors that could be used to predict whether immunotherapy drugs will be effective in a given patient.” The researchers “found that the number of genetic mutations present in cancer cells was the best predictor of tumor response to immunotherapy with checkpoint inhibitors,” […]